Skip to main content
TipRanks
Go Ultimate75% OFF

MaxCyte (MXCT) Stock Price & Analysis

84 Followers

MXCT Stock Chart & Stats

$1.18-$0.01(-0.84%)
At close: 4:00 PM EST
$1$1.25$1.5$1.75Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$1.15 - $1.28
52-Week Range
$0.64 - $1.81
Previous Close
$1.19
Volume
N/A
Average Volume (3M)
1.66M
Market Cap
$121.84M
Enterprise Value
$31.57M
Total Cash (Recent Filing)
$101.28M
Total Debt (Recent Filing)
$16.89M
Price to Earnings (P/E)
―
Beta
1.13
Next Earnings
Mar 16, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Recent revenue acceleration and raised guidance indicate improving customer demand across core products and strategic programs. If sustained, this growth can expand the installed base, increase consumables utilization, and improve operating leverage as revenue scales over the next several quarters.

Strong Gross Margins

Persistently high gross margins suggest the platform has attractive underlying unit economics and proprietary technology value. Maintaining margins in the high 70s would give MaxCyte meaningful capacity to fund product development, absorb commercial expansion costs, and improve profitability as volume grows.

Expanded Commercial Platform

Akron would broaden MaxCyte beyond its existing electroporation focus into reagents and ancillary materials used across cell and gene therapy programs. The larger addressable market, higher recurring mix, and stated cross-selling opportunity could make revenue more diversified and durable if integration succeeds.

Bears Say

Persistent Unprofitability

MaxCyte has not yet demonstrated sustained operating leverage, with its current cost base still far above revenue and profitability remaining deeply negative. Continued losses can consume capital, limit strategic flexibility, and make future growth dependent on successfully scaling revenue or reducing expenses.

Ongoing Cash Burn

Persistent negative operating and free cash flow means the business is not currently self-funding its operations or investments. Even with expected improvement, ongoing cash consumption raises funding risk and leaves less financial capacity to withstand delays in customer programs, milestones, or commercialization.

Acquisition Financing Risk

The Akron transaction materially increases near-term cash commitments and introduces debt service and deferred-payment obligations while MaxCyte remains loss-making. Management expects only $40 million to $45 million of cash at closing, reducing liquidity available for execution and unexpected integration costs.

MaxCyte News

MXCT FAQ

What was MaxCyte’s price range in the past 12 months?
MaxCyte lowest stock price was $0.64 and its highest was $1.81 in the past 12 months.
What is MaxCyte’s market cap?
MaxCyte’s market cap is $121.84M.
When is MaxCyte’s upcoming earnings report date?
MaxCyte’s next earnings report is estimated for Mar 16, 2027 (not yet confirmed), which is in 118 days.
How were MaxCyte’s earnings last quarter?
MaxCyte released its earnings results on Nov 10, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.078 by $0.028.
Is MaxCyte overvalued?
According to Wall Street analysts MaxCyte’s price is currently Undervalued.
Does MaxCyte pay dividends?
MaxCyte does not currently pay dividends.
What is MaxCyte’s EPS estimate?
MaxCyte’s EPS estimate is -0.07.
How many shares outstanding does MaxCyte have?
MaxCyte has 103,250,290 shares outstanding.
What happened to MaxCyte’s price movement after its last earnings report?
MaxCyte reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.078. Following the earnings report the stock price went down -13.077%.
Which hedge fund is a major shareholder of MaxCyte?
Hedge funds hold MaxCyte shares: the largest hedge-fund position in MaxCyte is 72,328,099 shares, and hedge funds decreased their holdings by 5.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology